high mobility group box 1 pseudogene 19Genealiases: []
Q-omics provides the consensus-scored HMGB1P19 profile across patient tissues and cancer cell-line models. HMGB1P19 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HMGB1P19 is differentially expressed in 11, with the highest sampling consensus in STAD. Additionally, HMGB1P19 RNA expression shows 14,299 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, STAD, and LUAD as cancer lineages where HMGB1P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB1P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB1P19 survival associations across molecular data types. HMGB1P19 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB1P19 RNA expression–survival associations across cancer types. High HMGB1P19 expression shows unfavorable associations in ACC, UCEC, THCA and KIRP, but favorable associations in UCS and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HMGB1P19 RNA expression.
This table summarizes HMGB1P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB1P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB1P19 shows higher tumor expression in STAD, KIRC, LUSC, BRCA, HNSC and COAD. The STAD box plot shows higher HMGB1P19 RNA expression in tumor versus normal tissue (log2 FC = +0.191, t-test p < 0.001).
This table shows molecular features associated with HMGB1P19 in patient tissues and cancer cell lines. In patient samples, HMGB1P19 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
